Table 2.
EZH2 protein expression (WB) in primary tumor by known prognostic factors and recurrence.
| Characteristic | Positive WB |
Negative WB |
Total |
P-valuea | |||
|---|---|---|---|---|---|---|---|
| N | % | N | % | N | % | ||
| Age (years)* | 0.1658 | ||||||
| ≤54 | 5 | 12.8% | 7 | 33.3% | 12 | 20.0% | |
| 55–69 | 28 | 71.8% | 11 | 52.4% | 39 | 65.0% | |
| ≥70 | 6 | 15.4% | 3 | 14.3% | 9 | 15.0% | |
| BMI (kg/m2)* | 0.7491 | ||||||
| <25 | 7 | 17.9% | 3 | 14.3% | 10 | 16.7% | |
| 25–34 | 18 | 46.2% | 10 | 47.6% | 28 | 46.7% | |
| ≥35 | 14 | 35.9% | 8 | 38.1% | 22 | 36.7% | |
| Stage | 1.0000 | ||||||
| I/II | 21 | 53.8% | 11 | 52.4% | 32 | 53.3% | |
| III/IV | 18 | 46.2% | 10 | 47.6% | 28 | 46.7% | |
| Tumor grade | 0.0779 | ||||||
| 1/2 | 29 | 74.4% | 20 | 95.2% | 49 | 81.7% | |
| 3 | 10 | 25.6% | 1 | 4.8% | 11 | 18.3% | |
| Tumor penetration | 0.7187 | ||||||
| Inner half | 18 | 46.2% | 11 | 52.4% | 29 | 48.3% | |
| Outer half | 18 | 46.2% | 6 | 28.6% | 24 | 40.0% | |
| Serosa | 2 | 5.1% | 1 | 4.8% | 3 | 5.0% | |
| Unknown | 1 | 2.6% | 3 | 14.3% | 4 | 6.7% | |
| Cytology | 0.7090 | ||||||
| Negative | 30 | 76.9% | 16 | 76.2% | 46 | 76.7% | |
| Positive | 5 | 12.8% | 4 | 19.0% | 9 | 15.0% | |
| Suspicious | 3 | 7.7% | 0 | 0.0% | 3 | 5.0% | |
| Unknown | 1 | 2.6% | 1 | 4.8% | 2 | 3.3% | |
| Vascular invasion | 0.0439 | ||||||
| Absent | 22 | 56.4% | 16 | 76.2% | 38 | 63.3% | |
| Present | 17 | 43.6% | 3 | 14.3% | 20 | 33.3% | |
| Unknown | 0 | 0.0% | 2 | 9.5% | 2 | 3.3% | |
| Nodal status | 0.7613 | ||||||
| Negative | 27 | 69.2% | 13 | 61.9% | 40 | 66.7% | |
| Positive | 10 | 25.6% | 6 | 28.6% | 16 | 26.7% | |
| Unknown | 2 | 5.1% | 2 | 9.5% | 4 | 6.7% | |
| Site of first recurrence | 0.1462 | ||||||
| Distant | 5 | 12.8% | 0 | 0.0% | 5 | 8.3% | |
| Loco-regional | 5 | 12.8% | 1 | 4.8% | 6 | 10.0% | |
| NED | 29 | 74.4% | 20 | 95.2% | 49 | 81.7% | |
| EZH2 mRNA* | 0.0944 | ||||||
| <3.6 | 3 | 7.7% | 6 | 28.6% | 9 | 15% | |
| 3.6–9 | 17 | 43.6% | 7 | 33.3% | 24 | 40% | |
| >9 | 19 | 48.7% | 8 | 38.1% | 27 | 45% | |
| Total | 39 | 65.0% | 21 | 35.0% | 60 | 100.0% | |
a
Monte-Carlo simulation-based tests excluding observations with values as unknown/suspicious: Spearman rank correlation coefficient tests for age, BMI and EZH2 mRNA, Pearson’s chi-square tests for tumor penetration and recurrence status, Fisher exact test for the rest of the prognostic factors.